Impact of drug-eluting stents on outcomes of patients with end-stage renal disease undergoing percutaneous coronary revascularization.

Revascularization in Patients With Multivessel Coronary Artery Disease and Chronic Kidney Disease: Everolimus-Eluting Stents Versus Coronary Artery Bypass Graft Surgery. J Am Coll Cardiol (2015) 1.57

Drug-Eluting Versus Bare-Metal Stents During PCI in Patients With End-Stage Renal Disease on Dialysis. J Am Coll Cardiol (2016) 1.41

Management of cardiovascular disease in patients with kidney disease. Nat Rev Cardiol (2013) 1.23

Efficacy of paclitaxel-eluting stent implantation in hemodialysis patients. Heart Vessels (2011) 0.81

Comparison of inflammatory response after implantation of sirolimus- and paclitaxel-eluting stents in patients on hemodialysis. Heart Vessels (2012) 0.80

Revascularization treatment in patients with coronary artery disease. Hippokratia (2008) 0.80

Chronic kidney disease is associated with adverse outcomes among elderly patients taking clopidogrel after hospitalization for acute coronary syndrome. BMC Nephrol (2013) 0.80

End-stage renal disease and drug-eluting stents: one small step forward. J Invasive Cardiol (2006) 0.79

Pharmacological and non pharmacological strategies in the management of coronary artery disease and chronic kidney disease. Curr Cardiol Rev (2015) 0.79

Use of drug-eluting stents in patients with coronary artery disease and renal insufficiency. Mayo Clin Proc (2010) 0.78

Revascularization options in patients with chronic kidney disease. Tex Heart Inst J (2010) 0.78

Dialysis Patients with Implanted Drug-Eluting Stents Have Lower Major Cardiac Events and Mortality than Those with Implanted Bare-Metal Stents: A Taiwanese Nationwide Cohort Study. PLoS One (2016) 0.76

Determinants of Mortality in Patients with Chronic Kidney Disease Undergoing Percutaneous Coronary Intervention. Cardiorenal Med (2016) 0.75

Coronary Stents in Patients with ST-Elevation Myocardial Infarction and Chronic Kidney Disease Undergoing Primary Percutaneous Coronary Intervention. Korean Circ J (2012) 0.75

Comparison of Drug-Eluting and Bare Metal Stents in Patients With Chronic Kidney Disease: An Updated Systematic Review and Meta-Analysis. J Am Heart Assoc (2016) 0.75

Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med (2007) 25.17

Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med (2006) 18.25

Third universal definition of myocardial infarction. J Am Coll Cardiol (2012) 8.59

2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. J Am Coll Cardiol (2011) 6.35

ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: developed in collaboration with the American College of Chest Physicians, American Thoracic Society, Inc., and the Pulmonary Hypertension Association. Circulation (2009) 5.49

2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J (2015) 5.15

Relationship of blood transfusion and clinical outcomes in patients with acute coronary syndromes. JAMA (2004) 5.11

2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. Circulation (2011) 5.09

Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention. N Engl J Med (2006) 5.07

Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials. Lancet (2002) 5.04

Association of blood transfusion with increased mortality in myocardial infarction: a meta-analysis and diversity-adjusted study sequential analysis. JAMA Intern Med (2013) 5.02

2014 AHA/ACC Guideline for the Management of Patients with Non-ST-Elevation Acute Coronary Syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol (2014) 4.57

Incidence and prognostic significance of thrombocytopenia in patients treated with prolonged heparin therapy. Arch Intern Med (2008) 3.68

Increased mortality among patients taking digoxin--analysis from the AFFIRM study. Eur Heart J (2012) 3.52

Lack of adverse clopidogrel-atorvastatin clinical interaction from secondary analysis of a randomized, placebo-controlled clopidogrel trial. Circulation (2003) 3.38

Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians. Circulation (2007) 3.34

Aspirin dose for the prevention of cardiovascular disease: a systematic review. JAMA (2007) 3.28

Thrombin-receptor antagonist vorapaxar in acute coronary syndromes. N Engl J Med (2011) 3.20

Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational study. Lancet (2013) 3.17

Consensus document: antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting. A North-American perspective. Thromb Haemost (2011) 3.16

Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease: the STRADIVARIUS randomized controlled trial. JAMA (2008) 3.09

Analysis of risk of bleeding complications after different doses of aspirin in 192,036 patients enrolled in 31 randomized controlled trials. Am J Cardiol (2005) 3.05

Delayed lead perforation: a disturbing trend. Pacing Clin Electrophysiol (2005) 2.92

Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial. JAMA (2004) 2.89

Stent thrombosis. J Am Coll Cardiol (2010) 2.86

ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol (2008) 2.67

Variability in platelet responsiveness to clopidogrel among 544 individuals. J Am Coll Cardiol (2005) 2.59

Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. J Am Coll Cardiol (2007) 2.56

2012 ACCF/AATS/SCAI/STS expert consensus document on transcatheter aortic valve replacement. J Am Coll Cardiol (2012) 2.44

Safety and efficacy of aspirin, clopidogrel, and warfarin after coronary stent placement in patients with an indication for anticoagulation. Am Heart J (2004) 2.42

Premature myocardial infarction novel susceptibility locus on chromosome 1P34-36 identified by genomewide linkage analysis. Am J Hum Genet (2004) 2.36

An analysis of mortality rates with dual-antiplatelet therapy in the primary prevention population of the CHARISMA trial. Eur Heart J (2007) 2.31

2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation (2014) 2.30

Bleeding complications with dual antiplatelet therapy among patients with stable vascular disease or risk factors for vascular disease: results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial. Circulation (2010) 2.27

Benefits of β blockers in patients with heart failure and reduced ejection fraction: network meta-analysis. BMJ (2013) 2.26

Early statin initiation and outcomes in patients with acute coronary syndromes. JAMA (2002) 2.23

Triple antiplatelet therapy during percutaneous coronary intervention is associated with improved outcomes including one-year survival: results from the Do Tirofiban and ReoProGive Similar Efficacy Outcome Trial (TARGET). J Am Coll Cardiol (2003) 2.17

Drug-eluting stents versus bare-metal stents in saphenous vein graft interventions: a systematic review and meta-analysis. JACC Cardiovasc Interv (2010) 2.14

Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled phase II study. Lancet (2009) 2.13

Incomplete inhibition of thromboxane biosynthesis by acetylsalicylic acid: determinants and effect on cardiovascular risk. Circulation (2008) 2.05

2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation (2014) 2.04

Brugada phenocopy in concomitant ethanol and heroin overdose. Ann Noninvasive Electrocardiol (2014) 2.02

ANG II infusion promotes abdominal aortic aneurysms independent of increased blood pressure in hypercholesterolemic mice. Am J Physiol Heart Circ Physiol (2009) 2.01

2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. Circulation (2011) 1.99

Platelet function monitoring in patients with coronary artery disease. J Am Coll Cardiol (2007) 1.97

Healing Achilles--sirolimus versus paclitaxel. N Engl J Med (2005) 1.91

Rapid dilation of the abdominal aorta during infusion of angiotensin II detected by noninvasive high-frequency ultrasonography. J Vasc Surg (2006) 1.91

Aspirin for primary prevention of cardiovascular events in people with diabetes: a position statement of the American Diabetes Association, a scientific statement of the American Heart Association, and an expert consensus document of the American College of Cardiology Foundation. Diabetes Care (2010) 1.86

Peripheral arterial disease in patients with end-stage renal disease: observations from the Dialysis Outcomes and Practice Patterns Study (DOPPS). Circulation (2006) 1.80

Adipocyte-specific deficiency of angiotensinogen decreases plasma angiotensinogen concentration and systolic blood pressure in mice. Am J Physiol Regul Integr Comp Physiol (2011) 1.79

Endothelial cell-specific deficiency of Ang II type 1a receptors attenuates Ang II-induced ascending aortic aneurysms in LDL receptor-/- mice. Circ Res (2011) 1.78

Smoking, clopidogrel, and mortality in patients with established cardiovascular disease. Circulation (2009) 1.77

Acute intramural hematoma of the aorta: a mystery in evolution. Circulation (2005) 1.76

Aspirin for primary prevention of cardiovascular events in people with diabetes: a position statement of the American Diabetes Association, a scientific statement of the American Heart Association, and an expert consensus document of the American College of Cardiology Foundation. Circulation (2010) 1.69

Potential impact of the HIPAA privacy rule on data collection in a registry of patients with acute coronary syndrome. Arch Intern Med (2005) 1.68

Time to coronary angiography and outcomes among patients with high-risk non ST-segment elevation acute coronary syndromes: results from the SYNERGY trial. Circulation (2007) 1.67

Lack of evidence of a clopidogrel-statin interaction in the CHARISMA trial. J Am Coll Cardiol (2007) 1.66

Lack of benefit from intravenous platelet glycoprotein IIb/IIIa receptor inhibition as adjunctive treatment for percutaneous interventions of aortocoronary bypass grafts: a pooled analysis of five randomized clinical trials. Circulation (2002) 1.65

2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. Catheter Cardiovasc Interv (2012) 1.65

ACCF/ACR/AHA/NASCI/SAIP/SCAI/SCCT 2010 expert consensus document on coronary computed tomographic angiography: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents. J Am Coll Cardiol (2010) 1.63

Impact of clopidogrel in patients with acute coronary syndromes requiring coronary artery bypass surgery: a multicenter analysis. J Am Coll Cardiol (2008) 1.62

Intravascular ultrasound evidence of angiographically silent progression in coronary atherosclerosis predicts long-term morbidity and mortality after cardiac transplantation. J Am Coll Cardiol (2005) 1.59

Obesity promotes inflammation in periaortic adipose tissue and angiotensin II-induced abdominal aortic aneurysm formation. Arterioscler Thromb Vasc Biol (2009) 1.59

2012 ACCF/AATS/SCAI/STS expert consensus document on transcatheter aortic valve replacement: developed in collaboration with the American Heart Association, American Society of Echocardiography, European Association for Cardio-Thoracic Surgery, Heart Failure Society of America, Mended Hearts, Society of Cardiovascular Anesthesiologists, Society of Cardiovascular Computed Tomography, and Society for Cardiovascular Magnetic Resonance. Ann Thorac Surg (2012) 1.59

Early and sustained survival benefit associated with statin therapy at the time of percutaneous coronary intervention. Circulation (2002) 1.58

Association of diabetes mellitus and glycemic control strategies with clinical outcomes after acute coronary syndromes. Am Heart J (2004) 1.58

Effect of vorapaxar on myocardial infarction in the thrombin receptor antagonist for clinical event reduction in acute coronary syndrome (TRA·CER) trial. Eur Heart J (2013) 1.56

Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention 1-year results from the STEEPLE (SafeTy and efficacy of enoxaparin in percutaneous coronary intervention patients, an international randomized evaluation) trial. JACC Cardiovasc Interv (2009) 1.56

Antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting: a North American perspective: executive summary. Circ Cardiovasc Interv (2011) 1.56

Pharmacologic rate versus rhythm-control strategies in atrial fibrillation: an updated comprehensive review and meta-analysis. Pacing Clin Electrophysiol (2012) 1.52

Drug-eluting stents in patients with end-stage renal disease: meta-analysis and systematic review of the literature. Catheter Cardiovasc Interv (2010) 1.51

Feasibility of simultaneous bilateral carotid artery stenting. Catheter Cardiovasc Interv (2004) 1.50

Comparison of results of carotid stenting followed by open heart surgery versus combined carotid endarterectomy and open heart surgery (coronary bypass with or without another procedure). Am J Cardiol (2005) 1.49

The influence of body mass index on mortality and bleeding among patients with or at high-risk of atherothrombotic disease. Eur Heart J (2009) 1.49

Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians. J Am Coll Cardiol (2007) 1.49

2015 ESC Guidelines for the Management of Acute Coronary Syndromes in Patients Presenting Without Persistent ST-segment Elevation. Rev Esp Cardiol (Engl Ed) (2015) 1.49

Bleeding, mortality, and antiplatelet therapy: results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial. Am Heart J (2011) 1.47

A brief, clinic-based, safer sex intervention for heterosexual African American men newly diagnosed with an STD: a randomized controlled trial. Am J Public Health (2009) 1.46

Transthoracic echocardiographic predictors of left atrial appendage thrombus. Am J Cardiol (2005) 1.46

ACCF/ACR/AHA/NASCI/SAIP/SCAI/SCCT 2010 expert consensus document on coronary computed tomographic angiography: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents. Circulation (2010) 1.45

Eplerenone is not superior to older and less expensive aldosterone antagonists. Am J Med (2012) 1.44

Early coronary revascularization diminishes the risk of ischemic stroke with acute myocardial infarction. Stroke (2006) 1.44

Prolonged infusion of angiotensin II in apoE(-/-) mice promotes macrophage recruitment with continued expansion of abdominal aortic aneurysm. Am J Pathol (2011) 1.43

Angiographic variables predict increased risk for adverse ischemic events after coronary stenting with glycoprotein IIb/IIIa inhibition: results from the TARGET trial. J Am Coll Cardiol (2003) 1.42

Is there an association between external cardioversions and long-term mortality and morbidity? Insights from the Atrial Fibrillation Follow-up Investigation of Rhythm Management study. Circ Arrhythm Electrophysiol (2011) 1.42

Fractionating heparins and their clinical trial data--something for everyone. JAMA (2004) 1.41

Superficial femoral artery occlusion: nitinol stents achieve better flow and reduce the need for medications than balloon angioplasty alone. J Invasive Cardiol (2003) 1.41

Bleeding-associated outcomes with preoperative clopidogrel use in on- and off-pump coronary artery bypass. J Thromb Thrombolysis (2012) 1.41

Basic cerebral anatomy for the carotid interventionalist: the intracranial and extracranial vessels. Catheter Cardiovasc Interv (2006) 1.41

Closure devices and vascular complications among percutaneous coronary intervention patients receiving enoxaparin, glycoprotein IIb/IIIa inhibitors, and clopidogrel. Catheter Cardiovasc Interv (2005) 1.40